Searched for: in-biosketch:true
person:shapij06
Response to "Cetrimonium Bromide Patch Test Positivity Is Found With a High Frequency in a Cohort of Patients With Frontal Fibrosing Alopecia"
Sikora, Michelle; Nohria, Ambika; Desai, Deesha; Senna, Maryanne M; Caplan, Avrom S; Shapiro, Jerry; Lo Sicco, Kristen
PMID: 38656914
ISSN: 2162-5220
CID: 5657622
Comment on 'Treatment of moderate-to-severe alopecia areata with baricitinib in preadolescent children'
Buontempo, Michael G; Sicco, Kristen Lo; Shapiro, Jerry
PMID: 37681491
ISSN: 1365-2133
CID: 5613502
Response to Corona-Rodarte et al.'s "Pressure alopecias: a review" [Comment]
Novice, Madison; Shapiro, Jerry; Lo Sicco, Kristen I
PMID: 37648065
ISSN: 1097-6787
CID: 5609242
Understanding perceptions of hair loss in hijab-wearing women: a pilot survey study
Alhanshali, Lina; Bawany, Fatima; Buontempo, Michael G; Shapiro, Jerry; Lo Sicco, Kristen
PMCID:10653569
PMID: 38028023
ISSN: 2352-6475
CID: 5617292
Seasonal Trends in Hair Loss: A Big Data Analysis of Google Search Patterns and Their Association with Seasonal Factors [Letter]
Buontempo, Michael G; Ingrassia, Jenne P; Shapiro, Jerry; Sicco, Kristen Lo
PMID: 37471104
ISSN: 1468-3083
CID: 5535962
Hydroxyurea-induced melanonychia [Case Report]
Buontempo, Michael G; Chaudhry, Zaima S; Raval, Ruchi S; Mourtzanakis, Kelly; Ramachandran, Vignesh; Shapiro, Jerry; Lo Sicco, Kristen
PMCID:10711113
PMID: 38090663
ISSN: 2352-5126
CID: 5589262
Establishing baselines of hair density measurements: Variations across ethnicity, scalp region, and measurement techniques: A systematic review
Buontempo, Michael G; Sperling, Leonard C; Alhanshali, Lina; Shapiro, Jerry; Lo Sicco, Kristen
PMID: 37604232
ISSN: 1097-6787
CID: 5598402
The financial burden of alopecia: a survey study
Ingrassia, Jenne P; Buontempo, Michael G; Alhanshali, Lina; Akoh, Christine C; Glick, Sharon; Shapiro, Jerry; Lo Sicco, Kristen
PMCID:10615414
PMID: 37915401
ISSN: 2352-6475
CID: 5736522
When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
King, Brett; Shapiro, Jerry; Ohyama, Manabu; Egeberg, Alexander; Piraccini, Bianca Maria; Craiglow, Brittany; Sinclair, Rodney; Chen, Yun-Fei; Wu, Wen-Shuo; Ding, Yuxin; Somani, Najwa; Dutronc, Yves
BACKGROUND:Baricitinib is approved for the treatment of adults with severe alopecia areata (AA). In the absence of robust data on the patterns of regrowth during treatment of severe AA, there is a gap in the knowledge regarding treatment expectations. OBJECTIVES/OBJECTIVE:To examine whether different clinical response subgroups could be identified in baricitinib-treated patients with severe AA and factors that contribute to these subgroups. METHODS:The BRAVE-AA1 and BRAVE-AA2 phase III trials enrolled patients with severe AA [Severity of Alopecia Tool (SALT) score ≥ 50 (≥ 50% scalp hair loss)]. Patients randomized to baricitinib 4 mg or 2 mg retained their treatment allocation for 52 weeks. Based on patterns identified through growth mixture modelling (GMM), patients were categorized into responder subgroups according to when they first achieved ≥ 30% improvement from baseline in SALT score (SALT30). For each responder subgroup, trajectories of response (i.e. achievement of a SALT score ≤ 20, SALT score ≤ 10 and ≥ 50% change from baseline in SALT score) and baseline disease characteristics are reported. RESULTS:Respectively, 515 and 340 patients were randomized to once-daily baricitinib 4 mg and 2 mg at baseline; 69% and 51%, respectively, achieved SALT30 at least once by week 52. Based on GMM findings, we identified three responder subgroups: early (SALT30 by week 12), gradual (SALT30 after week 12-week 36) and late (SALT30 after week 36-week 52). The proportions of early, gradual and late responders and nonresponders were, respectively, 33%, 28%, 8% and 31% among patients treated with baricitinib 4 mg, and 20%, 23%, 9% and 49%, respectively, among those treated with baricitinib 2 mg. Early responders had a shorter trajectory to maximal clinical outcomes (e.g. > 78% achieved a SALT score ≤ 20 by week 36) vs. gradual or late responders. Early responders were more frequent among patients with baseline severe AA (SALT score 50 to < 95) vs. very severe AA (SALT score 95-100). Overall, responders (early to late) were more frequent in patients with short (< 4 years) episodes of hair loss. CONCLUSIONS:These analyses identified early, gradual and late responder subgroups for scalp hair regrowth in baricitinib-treated patients with severe AA, and that these subgroups are influenced by baseline characteristics. Findings from these analyses will help to inform treatment expectations for scalp hair regrowth.
PMID: 37708254
ISSN: 1365-2133
CID: 5593332
Distribution of SALT scores by therapeutic response in patients with severe alopecia after 52 weeks of baricitinib therapy
Mesinkovska, Natasha; Senna, Maryanne; Mostaghimi, Arash; Seneschal, Julien; McMichael, Amy; Somani, Najwa; Lu, Na; Zou, Jianxiang; Jedynak, Jakub; Torisu-Itakura, Hitoe; Shapiro, Jerry
Introduction: In pivotal BRAVE-AA1 and AA2 phase 3 clinical trials, the Janus kinase (JAK)1/JAK2 inhibitor baricitinib has demonstrated efficacy in achieving clinically meaningful regrowth of hair in patients with severe alopecia areata. While a significant proportion of patients achieve regrowth by weeks 36 and 52 on baricitinib versus placebo, other patients, particularly those with longer episode duration or with higher disease severity, require more time on therapy to see full treatment benefit. The treatment benefit and distribution of SALT scores at Week 52 across the spectrum of responders is reported here. Methods: Adults with Severity of Alopecia Tool (SALT) score ≥50 (≥50% scalp hair loss) were enrolled into BRAVE-AA1 and BRAVE-AA2. Patients were randomized 2:2:3 to receive once-daily placebo (N=345), baricitinib 2 mg (BARI-2MG) (N=340), or baricitinib 4 mg (BARI-4MG) (N=515). Patients randomized to baricitinib retained their treatment allocation through Week 52. Pooled outcomes were assessed by baricitinib group and in patients with SALT score ≤20 versus SALT score >20 at Week 52. Median and interquartile range (IQR) of SALT scores was assessed with last observation carried forward. Results: At baseline, the median SALT score across 1200 randomized patients was 96 (near-total hair loss), with 638 (53.2%) having SALT score 95-100. At Week 52, 24.1% of patients who received BARI-2MG and 41.6% of patients who received BARI-4MG had SALT score ≤20; median (IQR) absolute SALT scores in this group were 7 (1-12) with BARI-2MG treatment and 3 (0-11) with BARI-4MG treatment. 17.9% of patients who received BARI-2MG and 18.8% of patients who received BARI-4MG patients achieved SALT scores of 21-49 at Week 52; median (IQR) scores were 34 (27-41) following BARI-2MG treatment and 31 (26-42) following BARI-4MG treatment. Conclusions: While a significant proportion of patients achieved SALT ≤20, the findings of this analysis indicate that partial benefit across scalp hair regrowth is achieved even if patients do not meet clinical response criteria of SALT ≤20. There is a substantial proportion of patients who demonstrate movement towards improvement across the SALT score spectrum. In these patients, a longer treatment course may be necessary to achieve optimal treatment outcomes.
SCOPUS:85177069086
ISSN: 2574-1624
CID: 5614812